Renewal of Provisional Consent to the Distribution of a New Medicine
In the notice published in the New Zealand Gazette,
17 February 2000, Issue No. 13, page 321, notice No. 1121 for Coumadin tablets add between lines 10 and 11, 16 and 17, and 22 and 23 Condition: Not to be marketed as substitutable for any other warfarin product as if the two products were bioequivalent.
Dated this 8th day of March 2000.
G. R. BOYD, Chief Advisor, Safety and Regulation, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.